Natera, Inc. (NTRA) News
Filter NTRA News Items
NTRA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NTRA News Highlights
- For NTRA, its 30 day story count is now at 7.
- Over the past 22 days, the trend for NTRA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DNA and ML are the most mentioned tickers in articles about NTRA.
Latest NTRA News From Around the Web
Below are the latest news stories about NATERA INC that investors may wish to consider to help them evaluate NTRA as an investment opportunity.
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR TestAUSTIN, Texas, December 28, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the federal District Court for the Middle District of North Carolina has issued a preliminary injunction, effective immediately, enjoining the RaDaR assay from NeoGenomics Labs, Inc. ("NeoGenomics"). |
13 High Growth Healthcare Stocks to BuyIn this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […] |
While Natera (NASDAQ:NTRA) shareholders have made 323% in 5 years, increasing losses might now be front of mind as stock sheds 4.7% this weekLong term investing can be life changing when you buy and hold the truly great businesses. And highest quality... |
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNAAUSTIN, Texas, December 21, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Molecular Oncology comparing the performance of mean tumor molecules per milliliter (MTM/mL) against mean variant allele frequency (mVAF) for measuring circulating tumor DNA (ctDNA), using Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test. The full study can be found here. |
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera PatentsAUSTIN, Texas, December 11, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware has issued an order denying CareDx’s motion for summary judgment on two Natera patents in the infringement lawsuit filed by Natera against CareDx. |
12 Best Genomics Stocks To Buy NowIn this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there’s one thing that can be said with certainty […] |
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023AUSTIN, Texas, December 06, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2023 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. |
Insider Sell Alert: Director Rowan Chapman Sells Shares of Natera Inc (NTRA)In the realm of stock market movements, insider trading activity is often a significant indicator that investors keep a close eye on. |
Insider Sell: CEO Steven Chapman Sells Shares of Natera Inc (NTRA)In a recent transaction on November 20, 2023, Steven Chapman, the CEO and President of Natera Inc, sold 2,566 shares of the company. |
Natera Announces Real-World Data Collaboration with MerckAUSTIN, Texas, November 14, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, under which Merck will utilize Natera’s real-world database (RWD) to advance oncology research. |